Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab and rituximab in primary Sjögren's syndrome
NL-OMON46078Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belimumab and rituximab in primary Sjögren's syndrome (4 arms), sponsored by GSK. Primary endpoint: Safety and tolerability. Started Mar 2016; status: active, not recruiting.
02
Drugs
belimumabrituximab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON46078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46078.